”Show me the incentive, and I will show you the outcome”. The famous quote from the great Munger. Read the last year report. Looked at holding of the management. The CEO (worked in the company since 2011, CEO since 2020) owns 10,000 shares (worth 6000$). The rest of the management owns between 0-1000 shares. The resigning chairman of the board owns 26,000 shares. The rest of the board owns more or less nothing (0-750 share). Unfortunately. Would look compelling otherwise.
Is it After the funding ”go-time”? I believe there is some value in the company (obviously) and with help by $clpt it can grow nice in the coming years.
Thanks for the reply🙏. IF I was Logos I would go all-in on the To7 in november. Its the perfect way to aquire a big chunck of shares to a hefty discountn(30%).
”Show me the incentive, and I will show you the outcome”. The famous quote from the great Munger. Read the last year report. Looked at holding of the management. The CEO (worked in the company since 2011, CEO since 2020) owns 10,000 shares (worth 6000$). The rest of the management owns between 0-1000 shares. The resigning chairman of the board owns 26,000 shares. The rest of the board owns more or less nothing (0-750 share). Unfortunately. Would look compelling otherwise.
Thoughts?
when these new board members take their seat, the expected outcome is they're going to rip the eyes out of the existing common shareholders
I wouldn't touch CLS until Logos Capital funds the company. It's in much too fragile of a state.
Is it After the funding ”go-time”? I believe there is some value in the company (obviously) and with help by $clpt it can grow nice in the coming years.
With a more secure balance sheet CLS is finally workable. They need to avoid urology for now though
Thanks for the reply🙏. IF I was Logos I would go all-in on the To7 in november. Its the perfect way to aquire a big chunck of shares to a hefty discountn(30%).